Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with
significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are …

Background Specific reversal agents for non–vitamin K antagonist oral anticoagulants are
lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …

Background It is uncertain whether bridging anticoagulation is necessary for patients with
atrial fibrillation who need an interruption in warfarin treatment for an elective operation or …

Methods We limited our literature review to trials in patients with AF and VTE because the
work of the Bleeding Academic Research Consortium has already addressed this issue in …

Background Appropriate antithrombotic regimens for patients with atrial fibrillation who have
an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) …

The aim of this updated statement is to provide comprehensive and timely evidence-based
recommendations on the prevention of stroke among individuals who have not previously …

Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anticoagulant …